COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab

Fabio Buttari, Antonio Bruno, Ettore Dolcetti, Federica Azzolini, Paolo Bellantonio, Diego Centonze, Roberta Fantozzi

Research output: Contribution to journalArticlepeer-review

Abstract

Since the recent approval of vaccines against COVID-19, efficacy concerns emerged for MS patients treated with immunosuppressive drugs. We report our experience in four patients, under cladribine (two) or under ocrelizumab (two) treatment, all with low lymphocyte count, three of them vaccinated after 3 months from the last dose with good immune response, one (under ocrelizumab) after 2 months, without developing an appropriate title of antibodies. This experience suggests that the discriminant for the response to the vaccine is not the lymphocyte count but the timing of the vaccination.

Original languageEnglish
Pages (from-to)102983
JournalMultiple Sclerosis and Related Disorders
Volume52
DOIs
Publication statusPublished - Jul 2021

Keywords

  • Antibodies, Monoclonal, Humanized
  • COVID-19
  • COVID-19 Vaccines
  • Cladribine
  • Humans
  • Multiple Sclerosis
  • SARS-CoV-2

Fingerprint

Dive into the research topics of 'COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab'. Together they form a unique fingerprint.

Cite this